Dudley Dawn M, Gao Yong, Nelson Kenneth N, Henry Kenneth R, Nankya Immaculate, Gibson Richard M, Arts Eric J
Department of Molecular Biology and Microbiology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Biotechniques. 2009 May;46(6):458-67. doi: 10.2144/000113119.
Replication studies on human immunodeficiency virus 1 (HIV-1) rely on a few laboratory strains that are divergent from dominant HIV-1 subtypes in the epidemic. Several phenotypic differences between diverse HIV-1 isolates and subtypes could affect vaccine development and treatment, but this research field lacks robust cloning/virus production systems to study drug sensitivity, replication kinetics, or to develop personalized vaccines. Extreme HIV-1 heterogeneity leaves few restriction enzyme sites for bacterial cloning strategies. In this study, we describe an alternative approach that involves direct introduction of any HIV-1 coding regions (e.g., any gene from a patient sample) into an HIV-1 DNA vector using yeast recombination. This technique uses positive and negative selectable markers in yeast and avoids the need for purification and screening of the DNA substrates and cloning products. Replication-competent virus is then produced from a modified mammalian 293T packaging cell line transfected with this yeast-derived HIV-1 vector. Although HIV-1 served as the prototype, this cloning strategy is now being developed for other diverse virus species such as hepatitis C virus and influenza virus.
人类免疫缺陷病毒1型(HIV-1)的复制研究依赖于少数几种实验室毒株,这些毒株与流行中的主要HIV-1亚型存在差异。不同HIV-1分离株和亚型之间的几种表型差异可能会影响疫苗开发和治疗,但该研究领域缺乏强大的克隆/病毒生产系统来研究药物敏感性、复制动力学或开发个性化疫苗。HIV-1的极端异质性使得细菌克隆策略可用的限制性酶切位点很少。在本研究中,我们描述了一种替代方法,该方法涉及使用酵母重组将任何HIV-1编码区(例如,来自患者样本的任何基因)直接引入HIV-1 DNA载体。该技术在酵母中使用正、负选择标记,避免了对DNA底物和克隆产物进行纯化和筛选的需要。然后,从用这种酵母衍生的HIV-1载体转染的改良哺乳动物293T包装细胞系中产生具有复制能力的病毒。虽然HIV-1是原型,但这种克隆策略目前正在针对其他多种病毒物种(如丙型肝炎病毒和流感病毒)进行开发。